<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor X, concentrate from human plasma: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor X, concentrate from human plasma: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor X, concentrate from human plasma: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104820" href="/d/html/104820.html" rel="external">see "Factor X, concentrate from human plasma: Drug information"</a> and <a class="drug drug_patient" data-topicid="105350" href="/d/html/105350.html" rel="external">see "Factor X, concentrate from human plasma: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45755740"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Coagadex</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F49488643"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F45786208"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d636cf3-41de-441e-b14f-aa688d0c6a65">Factor X deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Factor X deficiency:</b> Dose, dosing frequency, and duration are based on location and severity of bleeding, patient age, and the patient's clinical condition. In general, administration of 1 unit/kg of factor X will increase circulating factor X concentrations by ~1.7 units/dL in children &lt;12 years or by ~2 units/dL in children ≥12 years and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bleeding episodes:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis: </i>Adjust dose to clinical response and factor X trough concentration targeting ≥5 units/dL; do not exceed a peak of 120 units/dL</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 years: IV: Initial: 40 units/kg/dose twice weekly</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: IV: Initial: 25 units/kg/dose twice weekly</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 years: IV: 30 units/kg/dose. Repeat every 24 hours until bleeding stops.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: IV: 25 units/kg/dose. Repeat every 24 hours until bleeding stops.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Perioperative management of bleeding:</b> IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pre-surgery: </i>Formula to calculate dosage required is based on desired increase in factor X concentrations (may be expressed as units/dL or as %). The calculated dose should raise plasma factor X concentrations to a desired target of 70 to 90 units/dL (or % of normal) using the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:10em;">Dose (units) = Body weight (kg) x desired factor X increase (units/dL or % of normal) x 0.6</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>For example:</i> 25 kg x 30 (% increase) x 0.6 = 450 units factor X</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum daily dose: 60 units/kg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">The <b>estimated</b> factor X increase may be determined by the following equation:</p>
<p style="text-indent:-2em;margin-left:12em;">Estimated increase of factor X (units/dL or % of normal) = [Total dose administered (units) x 1.7] divided by body weight (kg)</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>For example:</i> [1,400 units x 1.7] divided by 35 kg = 68%</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Dose (units) = Body weight (kg) x desired factor X increase (units/dL or % of normal) x 0.5</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>For example:</i> 50 kg x 30 (% increase) x 0.5 = 750 units factor X</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum daily dose: 60 units/kg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:10em;">The <b>estimated</b> factor X increase may be determined by the following equation:</p>
<p style="text-indent:-2em;margin-left:12em;">Estimated increase of factor X (units/dL or % of normal) = [Total dose administered (units) x 2] divided by body weight (kg)</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>For example:</i> [1,400 units x 2] divided by 70 kg = 40%</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Post-surgery:</i> Children and Adolescents: Repeat pre-surgery dose as needed to maintain plasma factor X concentrations at ≥50 units/dL (or % of normal) until patient is no longer at risk of bleeding; maximum daily dose: 60 units/kg/<b>day</b></p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109874"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51109875"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F45786209"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104820" href="/d/html/104820.html" rel="external">see "Factor X, concentrate from human plasma: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d636cf3-41de-441e-b14f-aa688d0c6a65">Factor X deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Factor X deficiency:</b> Dose, dosing frequency, and duration are based on location and severity of bleeding, and the patient's clinical condition. In general, administration of factor X 1 unit/kg will increase circulating factor X levels by ~2 units/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bleeding episodes:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis:</i> Initial: 25 units/kg twice weekly. Adjust dose to clinical response and factor X trough levels targeting ≥ 5 units/dL; do not exceed a peak of 120 units/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> 25 units/kg/dose. Repeat every 24 hours until bleeding stops. Alternatively, a patient-specific dose to achieve a desired peak target can be calculated using the following equation. Adjust dose and frequency based on peak and trough factor X levels.</p>
<p style="text-indent:-2em;margin-left:8em;">Number of factor X units required = Body weight (kg) × desired factor X increase (units/dL or % of normal) × 0.5.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>For example:</i> 50 kg × 30 (units/dL increase) × 0.5 = 750 units factor X.</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum daily dose: 60 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Dosing should be tailored to maintain factor X trough at 10 to 20 units/dL and may consider higher trough of &gt;40 units/dL (Menegatti 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Perioperative management of bleeding:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pre-surgery</i>, the calculated dose should raise plasma factor X levels to 70 to 90 units/dL (or % of normal) using the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Number of factor X units required = Body weight (kg) × desired factor X increase (units/dL or % of normal) × 0.5.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>For example:</i> 50 kg × 30 (units/dL increase) × 0.5 = 750 units factor X.</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum daily dose: 60 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Post-surgery</i>, the calculated dose should maintain plasma factor X levels at ≥50 units/dL (or % of normal) until patient is no longer at risk of bleeding; Maximum daily dose: 60 units/kg/day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991360"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988538"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F45499989"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Reported adverse reactions are for adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site, infusion-site pain</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p></div>
<div class="block coi drugH1Div" id="F45360906"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Life-threatening hypersensitivity reactions to factor X (human) or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F45786198"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of inhibitory antibodies may occur. Factor X inhibitory antibodies should be measured when bleeding is not controlled and/or factor X levels are suboptimal after apparent adequate dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur with use; discontinue immediately if hypersensitivity reaction develops and initiate appropriate management.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human proteins: Contains traces of human proteins other than factor X.</p></div>
<div class="block foc drugH1Div" id="F45755741"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coagadex: 250 units (1 ea); 500 units (1 ea) [latex free]</p></div>
<div class="block geq drugH1Div" id="F45755739"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46105216"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Coagadex Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (per each): $13.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (per each): $13.07</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614628"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only. Administer at a rate of 10 to 20 mL/minute within 1 hour of reconstitution.</p></div>
<div class="block adm drugH1Div" id="F45786214"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only. Administer at a rate of 10 to 20 mL/minute within 1 hour of reconstitution.</p></div>
<div class="block sts drugH1Div" id="F45786200"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 30°C (36°F to 86°F); do not freeze. Protect from light. After reconstitution, use within 1 hour.</p></div>
<div class="block usep drugH1Div" id="F53571318"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis and treatment of bleeding episodes in patients with hereditary factor X deficiency and perioperative management of bleeding episodes in patients with mild and moderate hereditary factor X deficiency (FDA approved in pediatric patients [age not specified] and adults). <b>Note:</b> Perioperative management of bleeding in major surgery in patients with severe hereditary Factor X deficiency has not been studied.</p></div>
<div class="block cyt drugH1Div" id="F45525240"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45525237"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants (Inhibitors of Factor Xa): May diminish the therapeutic effect of Factor X (Human).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F45786196"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant patients with factor X deficiency may have an increased risk of bleeding following abortion, antenatal procedures, delivery, and miscarriage; close surveillance is recommended. Clotting factors should be monitored at the first antenatal visit, once or twice during the third trimester, at delivery, and prior to surgical or invasive procedures. Although factor X concentrations may increase during pregnancy, patients with severe deficiency remain at risk for bleeding. In addition, treatment may be needed if concentrations are &lt;0.3 IU/mL at term or prior to procedure. Hemostatic concentrations should be maintained for at least 3 days following procedures or postpartum. When available, factor X concentrate may be used (RCOG [Pavord 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53571317"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Bleeding; hypersensitivity reactions during infusion. Factor X concentrations, especially in the first week of treatment and with dosage changes; monitor for development of inhibitor antibodies by clinical observation (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor concentrations, Nijmegen-Bethesda assay). In surgical patients, measure Factor X concentrations at baseline and after surgery.</p></div>
<div class="block pha drugH1Div" id="F45786202"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces deficient clotting factor X needed for effective hemostasis. Factor X, an inactive zymogen, can be activated by factor IXa via the intrinsic pathway or by factor IIa via the extrinsic pathway. Factor X is then converted from its inactive form to the active form (factor Xa) by the cleavage of a 52-residue peptide from the heavy chain. Factor Xa associates with factor Va on the phospholipid surface to form the prothrombinase complex, which actives prothrombin to thrombin in the presence of calcium ions. Thrombin then acts upon soluble fibrinogen and factor XIII to generate a cross-linked fibrin clot.</p></div>
<div class="block phk drugH1Div" id="F45786204"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children ≥12 years, Adolescents, and Adults: 56.3 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Single dose: Children ≥12 years, Adolescents, and Adults: 30.3 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46972197"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Coagadex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Coagadex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Coagadex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Coagadex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Coagadex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Coagadex.1">
<a name="Coagadex.1"></a>Coagadex (Factor X [Human]) [prescribing information]. Durham, NC: BPL USA Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217097">
<a name="27217097"></a>Escobar MA, Auerswald G, Austin S, Huang JN, Norton M, Millar CM. Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery. <i>Haemophilia</i>. 2016;22(5):713-720. doi:10.1111/hae.12954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-x-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/27217097/pubmed" id="27217097" target="_blank">27217097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30559262">
<a name="30559262"></a>Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. <i>Blood</i>. 2019;133(5):415-424. doi:10.1182/blood-2018-06-820738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-x-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/30559262/pubmed" id="30559262" target="_blank">30559262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-x-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120813 Version 31.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
